UNSPSC 51422425: Hydrocortisone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C23H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X7931PO74, chemically known as pregn-4-ene-3,20-dione,11beta,17alpha,21-trihydroxy-,21 acetate but more generally known as hydrocortisone acetate, which bears US NIH Compound Identifier 3641. European Medicines Agency schedules Hydrocortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02562MIG.

UNSPSC 51422425 Hydrocortisone acetate, a Commodity code, shows limited recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The two recent opportunities tagged under this code diverge significantly from hydrocortisone acetate itself: Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems (not corticosteroids), while the Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription fulfillment models at the program level rather than procuring a specific pharmaceutical product. State and local health agencies and health benefit programs appear to be the primary issuing bodies when this code is applied, though the recent activity suggests broader procurement interest in emergency response pharmaceuticals and pharmacy benefit restructuring rather than hydrocortisone acetate specifically.

Geographic activity centers on Texas and Florida based on recent postings. The Seminole County opportunity (IFB, response due July 26, 2023) targets quarterly delivery of naloxone to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year term and one-year renewal option. The Texas HHS RFI (posted April 3, 2026, response due the same day) seeks vendor input on direct manufacturer contracting for prescription fulfillment across the state's pharmacy benefit program. Neither opportunity represents active procurement of hydrocortisone acetate; the code assignment appears inconsistent with the actual scope of work being solicited. Business development professionals should verify whether opportunities tagged under this code are genuinely seeking hydrocortisone acetate or whether misclassification is masking broader pharmaceutical or pharmacy-benefit procurement activity in specific jurisdictions.